News

March 22, 2019March 22, 2019

Polysplenia Syndrome a Risk Factor for Early PH, Study Suggests

News, PH News

People with polysplenia syndrome — a condition characterized by a “left-sidedness” on both sides of the body — have an increased risk for early development of pulmonary hypertension (PH), ... Read more

March 21, 2019March 21, 2019

Resverlogix Obtains Funding for Phase 2 Trial Testing Apabetalone in PAH

News, PAH News

Resverlogix announced that it has received funding from the Canadian Institutes for Health Research for a Phase 2 clinical study investigating the safety and efficacy of its proprietary therapy apabetalone (RVX-208) ... Read more

March 20, 2019March 20, 2019

Opsumit Has Potential to Improve Right Ventricle Function in PAH Patients, Phase 4 Data Show

News, PAH News

Treatment with Opsumit (macitentan) can significantly improve the heart’s right ventricular function, reverse cardiac tissue remodeling, and reduce pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH), preliminary ... Read more

March 18, 2019March 18, 2019

Cell Therapies Show Potential as Treatment for PAH, Review Finds

News, PAH News

Regenerative cell therapy can induce significant improvements in key clinical features of pulmonary arterial hypertension (PAH) in animal models, a review study shows. The study’s findings suggest that such ... Read more

March 15, 2019March 22, 2019

Defining Five Main Categories of Pulmonary Wellness: A Rehab Specialist’s Advice

News

“The whole is greater than the sum of its parts.” — Aristotle In today’s healthcare environment, an overwhelming percentage of resources are spent on treating diseases and their associated manifestations. ... Read more

March 15, 2019March 22, 2019

Estrogen May Help Protect Against Heart Changes in PAH, Animal Study Suggests

News, PAH News

Estrogen, one of the major female sex hormones, has a protective effect in pulmonary arterial hypertension (PAH) by halting oxidative stress and collagen deposition, a rat study suggests. The ... Read more

March 14, 2019March 19, 2019

Liquidia’s LIQ861 Safe and Effective in PAH Patients, Phase 3 Trial Suggests

News, PAH News

A Phase 3 clinical trial testing LIQ861 met its primary objective, showing that the investigational inhaled dry powder treprostinil formulation is safe and effective for the treatment of pulmonary arterial hypertension (PAH), according ... Read more

March 14, 2019March 20, 2019

Brexit Could Have Real Effects for UK Rare Disease Patients, Experts Warn

News

Madeline Collin, a 24-year-old activist with Gaucher disease, worries that patients like her will suffer deeply if Britain leaves the European Union (EU), as scheduled, at the end of ... Read more

March 13, 2019March 13, 2019

1st Participant Enrolled in Phase 2 Trial of Levosimendan for PH Patients with Heart Failure

News, PH News

The first participant has been enrolled in a Phase 2 trial testing the investigational therapy levosimendan in pulmonary hypertension (PH) patients with heart failure and preserved ejection fraction (PH-HFpEF). Ejection ... Read more

March 12, 2019March 12, 2019

Moral Dilemmas Complicate Treatment of Rare Diseases, Says Israeli Bioethicist

News

With each new advance in medicine comes ethical dilemmas, from fertility treatments and newborn screening, to vaccinations, gene therapies and euthanasia. But rare diseases and the expensive therapies needed ... Read more

Pin It on Pinterest